Research and Development

At Laboratorios Bagó, we maintain a strong commitment to research and development, focusing on the search for proprietary molecules, drug combinations and new dosage forms, as well as the evaluation of pharmacological profiles and their analytical–pharmaceutical development

PATENTS
0

With which we reaffirm our commitment and position our products at the forefront of modern therapeutics, meeting the highest international standards.

0

Related to manufacturing procedures and new pharmaceutical forms.

0

For the discovery of proprietary molecules.

0

Number of countries where we hold patents.

Main achievements

These milestones are the result of the scientific rigor of our research teams, made up of highly qualified professionals who work every day to find new therapeutic solutions to improve people’s health, well-being, and quality of life.

Main achievements

These milestones are the result of the scientific rigor of our research teams, made up of highly qualified professionals who work every day to find new therapeutic solutions to improve people’s health, well-being, and quality of life.

1934

Foundation of Laboratorios Bagó

1947

The IBI, Bagó Institute of Research, is established.

1950

First company in Argentina to manufacture penicillin-based antibiotics.

1960

First local company to export its products to Europe.

1968

Development of the first injectable antibiotic based on ampicillin in Argentina.

1970

Expansion to Uruguay, Chile, and Mexico.

1981

First molecule researched, developed, and commercialized in Latin America by an Argentine laboratory: Talniflumate

1988

Development and launch of the first global combination of amoxicillin with sulbactam.

2000

Expansion into new markets in Africa, Asia, and Europe.

2001

Development and worldwide commercialization of the first sublingual formulation of the anxiolytic alprazolam.

2002

Development and commercialization of a new tablet formulation of the anti-ulcer drug omeprazole

2013

European patent granted for the formulation, manufacturing process, and specific applications of sublingual alprazolam.

2016

Patent in China for the development of the first divisible dosage forms for the treatment of obesity, containing orlistat — the pure active ingredient.

2019

Inauguration of the new Injectable Production Unit at the La Plata Pharmaceutical Plant, equipped with state-of-the-art pharmaceutical technology.

2024

90th Anniversary of Laboratorios Bagó.

2025

Inauguration of the Bioanalytical Center at the La Plata production plant.